A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea

Clinical Infectious Diseases

Volumn 61, Issue 7, 2015, Pages 1043-1048

  Hook, Edward W ^a   Golden, Matthew ^b   Jamieson, Brian D ^c   Dixon, Paula B ^a   Harbison, Hanne S ^a   Lowens, Sylvan ^b   Fernandes, Prabhavathi ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Cempra Pharmaceuticals Inc   (United States)

Author keywords

antibiotic resistance; gonorrhea; solithromycin; STDs

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; PENICILLIN DERIVATIVE; SOLITHROMYCIN; ANTIINFECTIVE AGENT; MACROLIDE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASTHENIA; BACTERIUM CULTURE; CHLAMYDIASIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GONORRHEA; HUMAN; IN VITRO STUDY; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MYCOPLASMOSIS; NAUSEA; NEISSERIA GONORRHOEAE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; OPEN STUDY; PAPULE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT OUTCOME; VOMITING; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; MACROLIDES; MALE; MIDDLE AGED; NEISSERIA GONORRHOEAE; TRIAZOLES; YOUNG ADULT;

EID: 84942087886     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ478     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2012. Atlanta, GA: CDC, 2014. Available at: http://www.cdc.gov/std/stats12/default.htm. Accessed 1 July 2015
2. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163-70
3. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12):1-110
4. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590-4
5. Kuruvilla ME, Khan DA. Antibiotic allergy. In: Bennett JE, Dolin R, Blaser MJ, eds. Principles and practice of infectious diseases, 8th ed. Philadelphia: Elsevier Saunders, 2015:300
6. McLean CA, Wang SA, Hoff GL, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. Sex Transm Dis 2004; 31:73-8
7. Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment with Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012; 39:877-9
8. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994; 21:107-11
9. Kannan K, Vasquez-Laslop N, Mankin AS. Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel. Cell 2012; 151:508-20
10. Llano-Sotelo B, Dunkle J, Klepacki D, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother 2010; 54:4961-70
11. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of a new fluroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains including those with high-level antimicrobial resistance: potential treatment option for gonorrhea. Antimicrob Agents Chemother 2012; 56:2739-42
12. Jensen JS, Fernandes P, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and-susceptible Mycoplasma genitalium strains. Antimicrob Agents Chemother 2014; 58:3151-6
13. Roblin PM, Kohihoff SA, Parker C, Hammerschlag MR. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother 2010; 54:1358-9
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Wayne, PA: CLSI, 2013; 33:100-2
15. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens-a randomized clinical trial. Clin Infect Dis 2011; 52:163-70
16. Bachmann LH, Stephens J, Hughes A, Hook EW III. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following standard therapy for uncomplicated gonorrhea. J Clin Microb 2002; 40:3596-601
17. Williams JA, Ofner S, Batteiger BE, Fortenberry JD, Van Der Pol B. Duration of polymerase chain reaction-detectable DNA after treatment of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis infections in women. Sex Transm Dis 2014; 41:215-9